Zepbound's EU approval sparks cautious optimism for weight loss treatment

Zepbound (tirzepatide) was approved in the EU in late 2024 for weight loss. The drug works by reducing appetite and food intake, but doctors stress it should be paired with a lower-calorie diet and regular exercise. Early 2025 data from Germany, France, and the UK show slow adoption, mainly among obese patients with related health issues.

Zepbound helps people eat less by curbing hunger, but it doesn't require a specific diet. Patients may find it harder to finish meals, so smaller portions or more frequent snacks can help. Nutrient-dense foods—especially those high in protein—are recommended to support weight loss while on the medication.

Health experts suggest getting 10% to 35% of daily calories from protein during treatment. The general guideline for adults is 0.8 grams of protein per kilogram of body weight. Eating breakfast can also help control hunger and keep blood sugar steady throughout the day. The drug can be taken at any time, as food doesn't affect its performance. Diets like the Mediterranean plan or USDA guidelines align well with Zepbound's goals. However, most dieticians still advise balanced nutrition and calorie reduction for the best results. In early 2025, prescriptions remained low across key European markets. The majority went to patients with a BMI over 30—or over 27 with conditions like diabetes. Limited insurance coverage meant most users paid privately, and specialists were more likely to prescribe it than GPs.

Zepbound offers a new option for weight management, but its success depends on diet and lifestyle changes. Early prescription trends suggest cautious uptake, mostly among high-risk patients. Without broader reimbursement, access remains limited for now.